Johnson & Johnson (NYSE: JNJ) reported its third quarter 2024 earnings results today. Reported sales increased 5.2% year-over-year to $22.5 billion. GAAP earnings decreased 37.5% to $2.7 billion while EPS fell 34% to $1.11 compared to last year. Adjusted EPS was down 9% to $2.42. Revenue and earnings beat expectations. For full-year 2024, JNJ expects reported […]
Johnson & Johnson (NYSE: JNJ) reported its third quarter 2024 earnings results today. Reported sales increased 5.2% year-over-year to $22.5 billion. GAAP earnings decreased 37.5% to $2.7 billion while EPS fell 34% to $1.11 compared to last year. Adjusted EPS was down 9% to $2.42. Revenue and earnings beat expectations. For full-year 2024, JNJ expects reported […]
Johnson & Johnson (NYSE: JNJ) reported its third quarter 2024 earnings results today.
Reported sales increased 5.2% year-over-year to $22.5 billion.
GAAP earnings decreased 37.5% to $2.7 billion while EPS fell 34% to $1.11 compared to last year. Adjusted EPS was down 9% to $2.42.
Revenue and earnings beat expectations.
For full-year 2024, JNJ expects reported sales of $88.4-88.8 billion and adjusted EPS of $9.88-9.98.
The stock was down 1% in premarket hours on Tuesday.
